| Wed, 23 Aug 2017 15:35:20: | No need for 60%-plus discounts on Repatha, Amgen says, rolling out real-world data as backup
|
| Wed, 23 Aug 2017 14:04:37: | With IBD market set for major growth, AbbVie stands to benefit: analyst
|
| Wed, 23 Aug 2017 12:57:23: | Digital-minded Novartis taps Apple's ResearchKit for smartphone MS study
|
| Wed, 23 Aug 2017 11:17:51: | Ironwood zeroes in on primary care doctors with new gout combo med Duzallo
|
| Tue, 22 Aug 2017 23:58:00: | Pfizer's Eucrisa beats Dupixent to the DTC punch in eczema, thanks to first-to-market status
|
| Tue, 22 Aug 2017 19:06:17: | Flu season early bird Seqirus debuts Fluad TV ad campaign targeting seniors
|
| Tue, 22 Aug 2017 15:30:50: | Bidders line up for Teva's women's health unit in potential $2B sale
|
| Tue, 22 Aug 2017 15:24:37: | No big growth in 10 years for Big Pharma's workforce, but lots of restructuring
|
| Tue, 22 Aug 2017 14:16:20: | Shire CFO, along with analysts, tries to placate investors after surprise exit news sent shares south
|
| Mon, 21 Aug 2017 15:58:48: | Ironwood's gout franchise gets a lift with Duzallo combo approval
|
| Mon, 21 Aug 2017 12:42:45: | Novartis CEO opens door to cancer patient demanding ‘fair’ CAR-T pricing
|
| Sun, 20 Aug 2017 22:03:54: | Siri? Alexa? The doctor will see you now: As hands-free tech use grows, pharma has an opportunity
|
| Sun, 20 Aug 2017 19:51:02: | Sanofi shakes up agency team, adding WPP Group to media and creative partners
|
| Fri, 18 Aug 2017 15:04:20: | Thank you, Ken Frazier, for a mission impossible: Making pharma look good
|
| Fri, 18 Aug 2017 13:07:55: | FiercePharmaAsia—Zai Lab’s $115M IPO, Takeda-Stanford R&D deal, Chinese firms’ bids for Arbor
|
| Fri, 18 Aug 2017 11:04:57: | AstraZeneca's Lynparza, armed with new FDA nod, aims to regain share from Tesaro's Zejula
|
| Thu, 17 Aug 2017 19:43:34: | Lawmakers dig into 'skyrocketing' MS costs with probe into 7 drugmakers
|
| Thu, 17 Aug 2017 18:45:58: | Sanofi tip ends in $465M settlement between Mylan and DOJ
|
| Thu, 17 Aug 2017 15:21:02: | Novo Nordisk's new semaglutide trounces Lilly's scrappy Trulicity in diabetes trial
|
| Thu, 17 Aug 2017 14:29:47: | Valeant denies bypassing eye-device maker Iconlabs in M&A bid for lens tech
|
| Wed, 16 Aug 2017 20:51:08: | Dr. Reddy's revives ex-Novartis OTC brands with slate of new ad campaigns
|
| Wed, 16 Aug 2017 15:33:02: | Bristol-Myers puts up Opdivo-plus-Yervoy data, adding to combo-therapy mystery
|
| Wed, 16 Aug 2017 15:04:45: | Biocon pulls EU Herceptin biosim app but expects to return to the race next quarter
|
| Wed, 16 Aug 2017 12:17:13: | Johnson & Johnson CEO Alex Gorsky leaves Trump council as president breaks it up
|
| Tue, 15 Aug 2017 21:54:20: | Surprise: A short list of TV-ad drug risks is easier to recall, FDA study finds
|
